[
  {
    "ts": null,
    "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
    "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
    "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736791802,
      "headline": "Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025",
      "id": 132390023,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168184/image_1886168184.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive opportunities for investors.",
      "url": "https://finnhub.io/api/news?id=5893587e5fa3e91a37b6975c5ceac34f7fc311555b4dc90278e6109cce22d835"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 12:00 PM ETCompany ParticipantsJoaquin Duato - Chairman...",
    "url": "https://finnhub.io/api/news?id=e56fd61be06abff9e44cbeb078f21a63b2823a6377cba48aa1391c2c66258da9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736785632,
      "headline": "Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)",
      "id": 132389631,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 12:00 PM ETCompany ParticipantsJoaquin Duato - Chairman...",
      "url": "https://finnhub.io/api/news?id=e56fd61be06abff9e44cbeb078f21a63b2823a6377cba48aa1391c2c66258da9"
    }
  },
  {
    "ts": null,
    "headline": "J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug",
    "summary": "J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug",
    "url": "https://finnhub.io/api/news?id=94ff49b9c5e3791c67b83932bf73a23a079ab25c2774a335016598fc741d645c",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736785195,
      "headline": "J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug",
      "id": 132408115,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug",
      "url": "https://finnhub.io/api/news?id=94ff49b9c5e3791c67b83932bf73a23a079ab25c2774a335016598fc741d645c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal",
    "summary": "Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal",
    "url": "https://finnhub.io/api/news?id=ffae4d9add57f6212f7069c3724594f018ff3038994a55b18b8d643e344247a8",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736781180,
      "headline": "Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal",
      "id": 132408116,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal",
      "url": "https://finnhub.io/api/news?id=ffae4d9add57f6212f7069c3724594f018ff3038994a55b18b8d643e344247a8"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
    "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
    "url": "https://finnhub.io/api/news?id=acefd6c62b5e03c69f1a52f64769dcd68743f1fbdf4f7407acb14bb7b9c5ad1f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736773140,
      "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
      "id": 132407804,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 240-point climb",
      "url": "https://finnhub.io/api/news?id=acefd6c62b5e03c69f1a52f64769dcd68743f1fbdf4f7407acb14bb7b9c5ad1f"
    }
  },
  {
    "ts": null,
    "headline": "J&J to Buy Intra-Cellular for About $14 Billion",
    "summary": "-- Johnson & Johnson agreed to acquire Intra-Cellular Therapies , a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on Bloomberg...",
    "url": "https://finnhub.io/api/news?id=91b1fc7a5f18c3005e35667f610b34503bb6329543f2fa56b3db73d6df7a4c36",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736771562,
      "headline": "J&J to Buy Intra-Cellular for About $14 Billion",
      "id": 132388654,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "-- Johnson & Johnson agreed to acquire Intra-Cellular Therapies , a company focused on treatments for central nervous system disorders, for about $14.6 billion. Katie Greifeld reports on Bloomberg...",
      "url": "https://finnhub.io/api/news?id=91b1fc7a5f18c3005e35667f610b34503bb6329543f2fa56b3db73d6df7a4c36"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
    "summary": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
    "url": "https://finnhub.io/api/news?id=35f7f11489d2dd65b5f0ad8661db1e6bbf02ca68fe03f5836e3199a0176a3619",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736770500,
      "headline": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
      "id": 132407711,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson makes $15 billion bet on mental-health drugs",
      "url": "https://finnhub.io/api/news?id=35f7f11489d2dd65b5f0ad8661db1e6bbf02ca68fe03f5836e3199a0176a3619"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal",
    "summary": "Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal",
    "url": "https://finnhub.io/api/news?id=d87a69ae67636cfd8bd973f386962c2d6b8a4205561af77f8a58afa6c8e8f766",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736765820,
      "headline": "Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal",
      "id": 132408141,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal",
      "url": "https://finnhub.io/api/news?id=d87a69ae67636cfd8bd973f386962c2d6b8a4205561af77f8a58afa6c8e8f766"
    }
  },
  {
    "ts": null,
    "headline": "What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies",
    "summary": "Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has blockbuster potential. Learn more on ITCI stock here.",
    "url": "https://finnhub.io/api/news?id=6601418ab94c5b36e2ee70bc8174701ab53238ea5503e00180366c3c0ec84e5a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736764304,
      "headline": "What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies",
      "id": 132388163,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/166076219/image_166076219.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has blockbuster potential. Learn more on ITCI stock here.",
      "url": "https://finnhub.io/api/news?id=6601418ab94c5b36e2ee70bc8174701ab53238ea5503e00180366c3c0ec84e5a"
    }
  },
  {
    "ts": null,
    "headline": "Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals",
    "summary": "Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals",
    "url": "https://finnhub.io/api/news?id=e7a85d7d462fa4bf221c4c52d5339787192ea59ef11333767a3e6c35425a3179",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736755733,
      "headline": "Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals",
      "id": 132408142,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Intra-Cellular Therapies rallies as pharma companies buy up smaller rivals",
      "url": "https://finnhub.io/api/news?id=e7a85d7d462fa4bf221c4c52d5339787192ea59ef11333767a3e6c35425a3179"
    }
  },
  {
    "ts": null,
    "headline": "How Might Markets React To December Inflation Report",
    "summary": "On Wednesday, the Bureau of Labor Statistics will release the consumer price index for December 2024. Check out my thoughts on how markets could react.",
    "url": "https://finnhub.io/api/news?id=b49029848ba4b9b4275366a796a598cdf2cc4134437c32582fa5f5a1ed7393a0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736753400,
      "headline": "How Might Markets React To December Inflation Report",
      "id": 132387010,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1385769431/image_1385769431.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "On Wednesday, the Bureau of Labor Statistics will release the consumer price index for December 2024. Check out my thoughts on how markets could react.",
      "url": "https://finnhub.io/api/news?id=b49029848ba4b9b4275366a796a598cdf2cc4134437c32582fa5f5a1ed7393a0"
    }
  },
  {
    "ts": null,
    "headline": "J&J: agreement to acquire Intra-Cellular Therapies",
    "summary": "Johnson & Johnson reports that it has entered into a definitive agreement to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system disorders, for a total net...",
    "url": "https://finnhub.io/api/news?id=d464593ae99830859fb6058fd934d6582047efb4dbb8282b0f00d5733672163d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736753294,
      "headline": "J&J: agreement to acquire Intra-Cellular Therapies",
      "id": 132386866,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson reports that it has entered into a definitive agreement to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on central nervous system disorders, for a total net...",
      "url": "https://finnhub.io/api/news?id=d464593ae99830859fb6058fd934d6582047efb4dbb8282b0f00d5733672163d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.",
    "summary": "Acquisition includes CAPLYTA® , the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in...",
    "url": "https://finnhub.io/api/news?id=25efe53e1482fa971c5f12417e6503ce6f5e0643424ce23a181f5b7b6112a9d3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736749924,
      "headline": "Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.",
      "id": 132386524,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Acquisition includes CAPLYTA® , the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in...",
      "url": "https://finnhub.io/api/news?id=25efe53e1482fa971c5f12417e6503ce6f5e0643424ce23a181f5b7b6112a9d3"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck",
    "summary": "The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=b33bc3685b05e6a8be346a015f8a8af9b9a7e4bc8c922f065a275e858418769a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736747713,
      "headline": "Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck",
      "id": 132386393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182230084/image_2182230084.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=b33bc3685b05e6a8be346a015f8a8af9b9a7e4bc8c922f065a275e858418769a"
    }
  }
]